The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation-Reference-Cited by-同舟云学术

The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation

Published:2011-02-23 Issue:2 Volume:337 Page:547-556
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Piali Luca,Froidevaux Sylvie,Hess Patrick,Nayler Oliver,Bolli Martin H.,Schlosser Eva,Kohl Christopher,Steiner Beat,Clozel Martine

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference40 articles.

1. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney

2. 2-Imino-thiazolidin-4-one Derivatives as Potent, Orally Active S1P1Receptor Agonists

3. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology

4. Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation;Budd;J Immunol,1987

5. Lymphocyte Homing and Homeostasis

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathway analysis of peripheral blood CD8+ T cell transcriptome shows differential regulation of sphingolipid signaling in multiple sclerosis and glioblastoma;PLOS ONE;2024-06-11

2. 1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management;International Immunopharmacology;2024-04

3. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents;Pharmaceutics;2024-01-15

4. Impact of Disease Modifying Therapy on MS-Related Fatigue: A Narrative Review;Brain Sciences;2023-12-20

5. Role of sphingosine 1-phosphate (S1P) in sepsis-associated intestinal injury;Frontiers in Medicine;2023-09-08